Results 61 to 70 of about 1,018 (177)

Suboptimal paths of cruzain analyzed systems.

, 2019
The 500 suboptimal paths between THR14 and CYS25 residues were calculated for (A) cruzain apo form, (B) cruzain-peptide, (C) cruzain-compound 1, (D) cruzain-compound 2, (E) cruzain-peptide-compound 1 and (F) cruzain-peptide-compound 2 trajectories.
Lilian Hernández Alvarez (739728), Diego Enry Barreto Gomes (739732), Pedro Geraldo Pascutti (564220), Jorge Enrique Hernández González (739730)   +3 more
core   +1 more source

Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target

Beilstein Journal of Organic Chemistry, 2013
Inhibition of the Trypanosoma cruzi cysteine protease cruzain has been proposed as a therapeutic approach for the treatment of Chagas’ disease. Among the best-studied cruzain inhibitors to date is the vinylsulfone K777 (1), which has proven effective in ...
Jonathan W. Choy, Clifford Bryant, Claudia M. Calvet, Patricia S. Doyle, Shamila S. Gunatilleke, Siegfried S. F. Leung, Kenny K. H. Ang, Steven Chen, Jiri Gut, Juan A. Oses-Prieto, Jonathan B. Johnston, Michelle R. Arkin, Alma L. Burlingame, Jack Taunton, Matthew P. Jacobson, James M. McKerrow, Larissa M. Podust, Adam R. Renslo   +17 more
doaj   +1 more source

Plant Proteinase Inhibitor BbCI Modulates Lung Inflammatory Responses and Mechanic and Remodeling Alterations Induced by Elastase in Mice

BioMed Research International, Volume 2017, Issue 1, 2017., 2017
Background. Proteinases play a key role in emphysema. Bauhinia bauhinioides cruzipain inhibitor (BbCI) is a serine‐cysteine proteinase inhibitor. We evaluated BbCI treatment in elastase‐induced pulmonary alterations. Methods. C57BL/6 mice received intratracheal elastase (ELA group) or saline (SAL group). One group of mice was treated with BbCI (days 1,
Rafael Almeida-Reis, Osmar A. Theodoro-Junior, Bruno T. M. Oliveira, Leandro V. Oliva, Alessandra C. Toledo-Arruda, Camila R. Bonturi, Marlon V. Brito, Fernanda D. T. Q. S. Lopes, Carla M. Prado, Ariana C. Florencio, Mílton A. Martins, Caroline A. Owen, Edna A. Leick, Maria L. V. Oliva, Iolanda F. L. C. Tibério, Anastasia Kotanidou   +15 more
wiley   +1 more source

Comparison of generalized correlation coefficients of the analyzed cruzain systems.

, 2019
ΔGC matrices are represented as the subtraction of the apo form values from those corresponding to (A) cruzain-peptide, (B) cruzain-compound 1 and (C) cruzain-compound 2 systems, and as the subtraction of the cruzain-peptide from those calculated for (D)
Lilian Hernández Alvarez (739728), Diego Enry Barreto Gomes (739732), Pedro Geraldo Pascutti (564220), Jorge Enrique Hernández González (739730)   +3 more
core   +1 more source

Design and Synthesis of Cysteine Protease Inhibitors

Proceedings, 2017
We have been preparing new dipeptidyl inhibitors against parasitic cysteine proteases cruzain (related to Chagas disease) and rhodesain (related to Sleeping Sickness disease), and against human cathepsins. [...]
Florenci V. Gonzalez
doaj   +1 more source

CD8+ T Cell‐Mediated Immunity during Trypanosoma cruzi Infection: A Path for Vaccine Development?

Mediators of Inflammation, Volume 2014, Issue 1, 2014., 2014
MHC‐restricted CD8+ T cells are important during infection with the intracellular protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease. Experimental studies performed in the past 25 years have elucidated a number of features related to the immune response mediated by these T cells, which are important for establishing the ...
Fernando dos Santos Virgilio, Camila Pontes, Mariana Ribeiro Dominguez, Jonatan Ersching, Mauricio Martins Rodrigues, José Ronnie Vasconcelos, Edecio Cunha-Neto   +6 more
wiley   +1 more source

IEM confirms lack of surface-associated cruzain.

, 2013
A cruzain-specific gold-labeled secondary antibody identified cruzain on the cell surface of intracellular wild type and cruzain-deficient T. cruzi amastigotes.
Ivy Hsieh (174545), James H. McKerrow (113918), Patricia S. Doyle (345076), Doron C. Greenbaum (345078), Juan C. Engel (145730), Yuan M. Zhou (345077)   +5 more
core   +1 more source

Genetic Vaccination against Experimental Infection with Myotropic Parasite Strains of Trypanosoma cruzi

Mediators of Inflammation, Volume 2014, Issue 1, 2014., 2014
In earlier studies, we reported that a heterologous prime‐boost regimen using recombinant plasmid DNA followed by replication‐defective adenovirus vector, both containing Trypanosoma cruzi genes encoding trans‐sialidase (TS) and amastigote surface protein (ASP) 2, provided protective immunity against experimental infection with a reticulotropic strain ...
Adriano Fernando Araújo, Gabriel de Oliveira, Juliana Fraga Vasconcelos, Jonatan Ersching, Mariana Ribeiro Dominguez, José Ronnie Vasconcelos, Alexandre Vieira Machado, Ricardo Tostes Gazzinelli, Oscar Bruna-Romero, Milena Botelho Soares, Mauricio Martins Rodrigues, Marcelo T. Bozza   +11 more
wiley   +1 more source

Per-residue free energy decomposition of cruzain complexes.

, 2019
The side chain, backbone, polar and non-polar contributions of each residue are displayed for all the analyzed complexes, i. e, (A) cruzain-compound 1 and (B) cruzain-compound 2, (C) cruzain-peptide, (D) cruzain-peptide-compound 1 and (E) cruzain-peptide-
Lilian Hernández Alvarez (739728), Diego Enry Barreto Gomes (739732), Pedro Geraldo Pascutti (564220), Jorge Enrique Hernández González (739730)   +3 more
core   +1 more source

Trypanosoma cruzi Infection and Host Lipid Metabolism

Mediators of Inflammation, Volume 2014, Issue 1, 2014., 2014
Trypanosoma cruzi is the causative agent of Chagas disease. Approximately 8 million people are thought to be affected worldwide. Several players in host lipid metabolism have been implicated in T. cruzi‐host interactions in recent research, including macrophages, adipocytes, low density lipoprotein (LDL), low density lipoprotein receptor (LDLR), and ...
Qianqian Miao, Momar Ndao, Marcelo T. Bozza   +2 more
wiley   +1 more source